Literature DB >> 16519827

Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist?

Maisa M Quintal1, Luis A Magna, Marbele S Guimaraes, Thais Ruano, Ubirajara Ferreira, Athanase Billis.   

Abstract

OBJECTIVE: In the 1997 TNM staging system, tumors were classified into a single subdivision: T2a, and bilateral tumor involvement (T2b). In the 2002 TNM staging system, tumors are subclassified as T2a (less than one half of one lobe involvement), T2b (more than one half of one lobe involvement), and T2c (bilateral involvement). A recent study questioned the existence of a true pathologic pT2b tumor. The aim of our study is to verify this question.
MATERIALS AND METHODS: The study population consisted of 224 men submitted to radical retropubic prostatectomy. The surgical specimens were histologically evaluated by complete embedding and whole-mount processing. Tumor extent was evaluated by a point-count method. The surgical specimens were staged according to the 2002 TNM staging system.
RESULTS: Using the 2002 TNM criteria, the surgical specimens were classified as pT2a, 28 (12.50%); pT2b, 0 (0%); pT2c, 138 (61.61%); pT3a, 30 (13.39%); and, pT3b, 28 (12.50%). Using the point-count method for tumor extent evaluation, the minimum and maximum total points obtained in unilateral tumors were 192 and 368 points, respectively; the most extensive unilateral tumor showed 68 positive points (less than half the minimum total point-count).
CONCLUSIONS: Using the point-count method for tumor extent, our study questions a real existence for pathologic stage pT2b tumors (unilateral tumors involving greater than one-half of one lobe).

Entities:  

Mesh:

Year:  2006        PMID: 16519827     DOI: 10.1590/s1677-55382006000100007

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  2 in total

1.  Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?

Authors:  Athanase Billis; Luciana L Meirelles; Leandro L L Freitas; Luis A Magna; Leonardo O Reis; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2011-02-20       Impact factor: 2.370

Review 2.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.